Press "Enter" to skip to content

U.S. FDA approves Stemline Therapeutics’ rare blood disease treatment

This is the first approved treatment for the condition, blastic plasmacytoid dendritic cell neoplasm (BPDCN), Richard Pazdur, director of the FDA’s Oncology Center of Excellence, said.

Original source:

Also Read:   Cipla may raise bar with digital therapeutics push